Standardized Expression of 18F-NAV4694 and 11C-PiB β-Amyloid PET Results with the Centiloid Scale
暂无分享,去创建一个
Vincent Doré | Christopher C Rowe | Kenneth Young | Svetlana Pejoska | Victor L Villemagne | C. Rowe | R. Mulligan | Gareth Jones | V. Villemagne | V. Doré | J. Chan | S. Pejoska | Gareth Jones | Rachel S Mulligan | Laura Margison | J Gordon Chan | K. Young | Laura Margison | Svetlana Pejoska
[1] Rik Ossenkoppele,et al. Comparison of Simplified Parametric Methods for Visual Interpretation of 11C-Pittsburgh Compound-B PET Images , 2014, The Journal of Nuclear Medicine.
[2] Masanori Ichise,et al. PET Quantification of 18F-Florbetaben Binding to β-Amyloid Deposits in Human Brains , 2013, The Journal of Nuclear Medicine.
[3] Chengjie Xiong,et al. Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer’s Disease: Results from the DIAN Study Group , 2016, PloS one.
[4] S. DeKosky,et al. Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[5] C. Rowe,et al. Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.
[6] Paul Maruff,et al. Research and standardization in Alzheimer's trials: Reaching international consensus , 2013, Alzheimer's & Dementia.
[7] E. Salmon,et al. 18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.
[8] Christer Halldin,et al. Clinical Validation of 18F-AZD4694, an Amyloid-β–Specific PET Radioligand , 2012, The Journal of Nuclear Medicine.
[9] Lennart Thurfjell,et al. The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data , 2015, Alzheimer's & Dementia.
[10] Lars Farde,et al. Characterization of AZD4694, a novel fluorinated Aβ plaque neuroimaging PET radioligand , 2010, Journal of neurochemistry.
[11] James Robert Brašić,et al. In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18) , 2010, Journal of Nuclear Medicine.
[12] R. Coleman,et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study , 2012, The Lancet Neurology.
[13] Robert A. Koeppe,et al. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET , 2015, Alzheimer's & Dementia.
[14] Nelleke Tolboom,et al. Image-derived input functions for PET brain studies , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[15] C. Rowe,et al. Quantitative approaches to amyloid imaging. , 2011, Methods in molecular biology.
[16] L. Thurfjell,et al. Automated quantification of [18F]flutemetamol data - Comparison with standard of truth based on histopathology , 2013 .
[17] Gina N. LaRossa,et al. [11C]PIB in a nondemented population , 2006, Neurology.
[18] R. Boellaard,et al. Test-retest variability of quantitative [11C]PIB studies in Alzheimer’s disease , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[19] S. DeKosky,et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] M. Mintun,et al. Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods , 2013, The Journal of Nuclear Medicine.
[21] Victor L. Villemagne,et al. Brain Amyloid Imaging , 2011, The Journal of Nuclear Medicine.